Extensive Application of Global Chronic Obstructive Pulmonary Disease Market in Prevention, Diagnostic and Treatment to Drive Market Growth, 2025

Researchmoz added Most up-to-date research on "Extensive Application of Global Chronic Obstructive Pulmonary Disease Market in Prevention, Diagnostic and Treatment to Drive Market Growth, 2025" to its huge collection of research reports.

Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow The main symptoms include shortness of breath and cough with sputum production. COPD is a progressive disease, meaning it typically worsens over time. Eventually everyday activities, such as walking or getting dressed, become difficult Chronic bronchitis and emphysema are older terms used for different types of COPD.

Globally the market for COPD is increasing rapidly. The major factor that derives the growth of COPD is the increasing growth in smoking in adults. Furthermore increasing pollution in the environment and increasing asthma patients are increasing the growth of COPD market.
In 2018, the global Chronic Obstructive Pulmonary Disease market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Chronic Obstructive Pulmonary Disease status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Chronic Obstructive Pulmonary Disease development in United States, Europe and China.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=2057247

The key players covered in this study
AstraZeneca
GSK
MSD
Sunovion
Novartis
Roche Group
Pfizer
Jubilant Pharma Limited
Almirall
Horizon Pharma
Boehringer Ingelheim

Market segment by Type, the product can be split into
Bronchodilators
Glucocorticoids
Other

Browse TOC @ https://www.researchmoz.us/global-chronic-obstructive-pulmonary-disease-market-size-status-and-forecast-2019-2025-report.html/toc

Market segment by Application, split into
Prevention
Diagnostic
Treatment

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Chronic Obstructive Pulmonary Disease status, future forecast, growth opportunity, key market and key players.
To present the Chronic Obstructive Pulmonary Disease development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Chronic Obstructive Pulmonary Disease are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Symptoms Of Chronic Obstructive Pulmonary Disease Including Shortness Of Breath, Wheezing, Chest Tightness, Cough - Global Drug Forecast and Market Analysis to 2025

ResearchMoz presents this most up-to-date research on "Symptoms Of Chronic Obstructive Pulmonary Disease Including Shortness Of Breath, Wheezing, Chest Tightness, Cough - Global Drug Forecast and Market Analysis to 2025".

Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by an abnormal inflammatory response and airflow obstruction that is not fully reversible. Chronic airflow limitation is caused by both small airway diseases, such as obstructive bronchiolitis, as well as parenchymal destruction, including emphysema. Research suggests that the pathogenesis of COPD involves both genetic and environmental factors. The fourth leading cause of death in the world, COPD progresses slowly and symptoms, including shortness of breath, wheezing, chest tightness, cough, and increased mucous production, worsen over time. Although it is currently unknown if the damage to the airways and lungs can be reversed, treatments and lifestyle changes can help slow the progress of the disease .

GlobalData estimates the 2015 sales for the COPD market at approximately $9.9 billion across the 8MM, encompassing the US, the five major European Union countries (5EU: France, Germany, Italy, Spain, and UK), Japan, and Australia. Over the course of the 10-year forecast period, the COPD market will grow at a Compound Annual Growth Rate (CAGR) of 3.7% across the 8MM. Each of the 8MM are anticipated to grow significantly, recording CAGRs of 3.7%, 5.2%, 4.3%, and 6.6% across the US, 5EU, Japan, and Australia, respectively. At the end of 2025, the US will account for 77.8% of sales across the 8MM, while the 5EU, Japan, and Australia will account for around 19.2%, 2.4%, and 0.7% of sales, respectively. The higher sales numbers for the US can be attributed to the higher prices of pharmaceuticals and the greater diagnosed prevalence of COPD in the region, as well as the anticipated high annual cost of therapy (ACOT) of GSK’s Nucala and AstraZeneca’s benralizumab in the US market.

Key Questions Answered
How will the COPD market landscape in the 8MM (US, France, Germany, Italy, Spain, UK , Japan, and Australia) change from 2015–2025?
What are the most promising late-stage pipeline drugs in COPD?
How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
What are the greatest unmet needs in COPD? Will the pipeline drugs fulfil these needs of the market?
What are the largest opportunities in the COPD landscape?

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1142784

Scope
Overview of COPD, including epidemiology (mMRC and CAT patient population), etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
Topline COPD market revenue from 2015–2025. ACOT and major pipeline product sales in this forecast period are included.
Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting COPD therapeutics sales in the 8MM.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
Analysis of the current and future market competition in the global COPD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global COPD therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the COPD therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Companies mentioned
AstraZeneca
Boehringer Ingelheim
Chiesi
GSK
Novartis
Sunovion

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1142784